NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 169
(Total Views: 222)
Posted On: 05/12/2023 4:53:52 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2023 Financial Report, Corporate Updates
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter 2023, the period ended March 31, 2022. Key takeaways from the report include that the company closed on a $26.5million with a public offering and registered direct offering, raising funds that BEAT anticipates using to execute on upcoming clinical, regulatory and commercial milestones as well as extend cash runway into late 2024. In addition, the report noted that HeartBeam has adjusted its strategic focus to support timely delivery of the company’s game-changing, ambulatory VECG products — HeartBeam AIMI(TM) and HeartBeam AIMIGo(TM) — as well as completed the acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system including the FDA-cleared Halo+(TM) Atrial Fibrillation Detection System. Earlier this year, senior medical technology executive Robert Eno became president of the company as well. “In the first quarter of 2023 we continued to position the company for the expected clearances and commercialization of the HeartBeam AIMIGo 12-Lead 3D vector electrocardiogram device,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “We recently closed $26.5 million in common stock-only financings to fund operations into late 2024. Proceeds will be used to fund development and regulatory work for the HeartBeam AIMIGo VECG device and to ready the product for initial commercialization during 2024. Our strategic focus is to enable timely delivery of our ambulatory VECG products, our key future value drivers, by first obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo VECG device. We expect to submit this application in the coming days. This will be followed by a second FDA application on the system’s ability to synthesize a 12-lead electrocardiogram (ECG). We currently estimate that we will submit this second application to the FDA in late 2023 and pursue initial commercialization in 2024.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter 2023, the period ended March 31, 2022. Key takeaways from the report include that the company closed on a $26.5million with a public offering and registered direct offering, raising funds that BEAT anticipates using to execute on upcoming clinical, regulatory and commercial milestones as well as extend cash runway into late 2024. In addition, the report noted that HeartBeam has adjusted its strategic focus to support timely delivery of the company’s game-changing, ambulatory VECG products — HeartBeam AIMI(TM) and HeartBeam AIMIGo(TM) — as well as completed the acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system including the FDA-cleared Halo+(TM) Atrial Fibrillation Detection System. Earlier this year, senior medical technology executive Robert Eno became president of the company as well. “In the first quarter of 2023 we continued to position the company for the expected clearances and commercialization of the HeartBeam AIMIGo 12-Lead 3D vector electrocardiogram device,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “We recently closed $26.5 million in common stock-only financings to fund operations into late 2024. Proceeds will be used to fund development and regulatory work for the HeartBeam AIMIGo VECG device and to ready the product for initial commercialization during 2024. Our strategic focus is to enable timely delivery of our ambulatory VECG products, our key future value drivers, by first obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo VECG device. We expect to submit this application in the coming days. This will be followed by a second FDA application on the system’s ability to synthesize a 12-lead electrocardiogram (ECG). We currently estimate that we will submit this second application to the FDA in late 2023 and pursue initial commercialization in 2024.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)